コーパス検索結果 (left1)
通し番号をクリックするとPubMedの該当ページを表示します
4 diamine tetramethylene phosphonic acid ((153)Sm-EDTMP) therapy for osteosarcoma is being investigated
5 ediaminetetramethylene phosphonic acid ((153)Sm-EDTMP), (179m)SnCl, and (166)Ho-Labeled 1,4,7,10-tetr
7 BPC or marrow infusion on day +14 after (153)Sm-EDTMP, recovery of hematopoiesis was problematic in t
10 1 and 22 (and day 43 for cohort 6), and (153)Sm-EDTMP was administered on day -1 to 1 of each cycle.
14 his study, we analyzed the influence of (153)Sm-EDTMP administered activity (AA), osteosarcoma tumor
16 Because the dose-limiting toxicity of (153)Sm-EDTMP is thrombocytopenia, a dose-escalation trial us
17 ffects of intravenous administration of (153)Sm-EDTMP on the developing physeal and articular cartila
18 ed in a phase I or II clinical trial of (153)Sm-EDTMP were analyzed using the 3-dimensional radiobiol
22 ylenediaminetetramethylene phosphonate ((153)Sm-EDTMP) is an effective component of multimodality the
23 ene diamine tetramethylene phosphonate ((153)Sm-EDTMP), a bone-seeking radiopharmaceutical, provides
25 is a bone-seeking radionuclide, whereas (153)Sm-EDTMP is a bone-seeking tetraphosphonate; both have b
28 /kg), 1 day prior to and 1 day following 153-Sm-EDTMP (22.5 MBq) showed a significantly prolonged med
29 g), or a single nonmyeloablative dose of 153-Sm-EDTMP (22.5 MBq) were 21, 22, and 28 days, respective
32 not differ between animals treated with 153-Sm-EDTMP alone versus those treated with the combination
WebLSDに未収録の専門用語(用法)は "新規対訳" から投稿できます。